Quantcast
Last updated on April 19, 2014 at 1:20 EDT

Latest Rasburicase Stories

2011-09-07 07:30:00

SAN DIEGO, Sept. 7, 2011 /PRNewswire/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) announced today that it has completed formal End-of-Phase 2 meetings with the U.S. Food and Drug Administration (FDA) and successfully reached agreement on the following key aspects of its proposed lesinurad Phase 3 development plan: the overall size and design of the planned Phase 3 clinical studies, the primary endpoints, the total safety database proposed for NDA filing, manufacturing plans for both drug...

2011-08-16 23:25:47

As an alternative to a conventional treatment for gout that some patients may not respond to, patients with severe, chronic gout who received the medication pegloticase for 6 months had greater improvement in measures of uric acid levels as well as physical function and quality of life, according to a study in the August 17 issue of JAMA. Long-term urate (a salt derived from uric acid) lowering therapy in gout aims to maintain concentrations of uric acid (UA) below a certain level. However,...

2010-09-14 16:52:00

SILVER SPRING, Md., Sept. 14 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Krystexxa (pegloticase) to treat the painful condition known as gout in adults who do not respond to or who cannot tolerate conventional therapy. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO) (Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO) Gout occurs due to an excess of the bodily waste uric acid, which is eventually deposited as needle-like crystals...

2009-10-16 16:31:00

BRIDGEWATER, N.J., Oct. 16 /PRNewswire-FirstCall/ -- Sanofi-aventis U.S. announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Elitek® (rasburicase) to be used for the initial management of plasma uric acid (PUA) levels in adult patients with leukemia, lymphoma, and solid tumor malignancies who are receiving anti-cancer therapy expected to result in tumor lysis syndrome (TLS) and subsequent elevations of plasma uric acid....

2009-02-14 13:27:05

The U.S. Food and Drug Administration has approved a new drug for gout, the first new prescription for the painful condition in 40 years, its maker says. Takeda Pharmaceuticals North America Inc. of Deerfield, Ill., said Friday its Uloric drug has been approved by the FDA for the more than 5 million U.S. victims of gout, a malady characterized by intense pain, inflammation and warmth in affected joints, the Chicago Tribune reported. The newspaper said most doctors use well-established...

2008-12-06 11:00:00

- Results Presented at ASH Annual Meeting - SAN FRANCISCO, Dec. 6 /PRNewswire-FirstCall/ -- Sanofi-aventis today announced results of a randomized phase III study presented at the 50th Annual Meeting of the American Society of Hematology. The study in adult patients with hematological malignancies at high or potential risk for tumor lysis syndrome (TLS) demonstrated that Elitek(R) (rasburicase) significantly reduced plasma uric acid (PUA) levels compared to allopurinol alone (p=0.0012). The...